HEP DART 2019: Frontiers in Drug Development for Hepatology

摘要/项目摘要： HEP DART：肝病学药物开发前沿是一个独立的两年一度的会议 在过去的24年里吸引了至少250名与会者。HEP DART对任何有兴趣的人开放， 治疗病毒性肝炎和慢性肝病。本次会议的内容制定， 主要关注科学家和临床研究人员，重点是药物开发， 疫苗学HEP DART 2019的目的是聚集临床医生，研究人员，基础科学家，护士 和医生助理一起推进我们对正在进行的药物开发的了解 治疗病毒性肝炎（HBV、HCV、HDV、HAV和HEV）的过程，非酒精性 脂肪性肝炎（NASH）和肝细胞癌（HCC）。HEP DART将独特地融合 生物学、化学、药理学和临床研究领域，为科学界提供 随着对肝脏感染治疗中当前和未来挑战的理解的增加， 疾病和癌症。注意事项：（1）强调抗病毒性肝炎药物开发的进展 如HBV、HCV和HDV。(2)描述HBV治疗策略的最新进展。（三） 强调针对NASH、纤维化和HCC的药物开发进展。(4)描述了新颖 病毒性肝炎、肝病和治疗结果的生物标志物。(5)审查当前治疗， 病毒性肝炎的疫苗接种指南;描述改进治疗方案的进展。（六） 了解HBV感染和NASH在儿科和青少年人群中的后果。（七） 评估疫苗和治疗性疫苗在未来病毒性肝炎、NASH和 与艾滋病毒合并感染(8)了解HDV、HAV和HEV的流行病学和发病机制。 方法：HEP DART 2019包括为期四天的科学报告，以口头和口头两种方式进行 和海报演示格式通过非并行会议。埃默里大学办公室 继续医学教育指定HEP DART最多24个类别1学分， AMA医师表彰奖。HEP DART提供了一个轻松和科学的刺激 为博士和医学博士建立网络和一起学习的氛围。请求提供支助， 青年调查员、妇女、有色少数群体和其他 代表人数不足

Abstract/ Project summary: HEP DART: Frontiers in Drug Development for Hepatology is an independent biennial conference attracting at least 250 attendees for the past 24 years. HEP DART is open to anyone interested in therapies for viral hepatitis and chronic liver disease. The content of this conference was developed to interest primarily scientists and clinical researchers with a focus on drug development and vaccinology. The aim of HEP DART 2019 is to assemble clinicians, researchers, basic scientists, nurses and physician assistants together to advance our knowledge of the ongoing drug development processes in the treatment of viral hepatitis (HBV, HCV, HDV, HAV and HEV), non‐‐‐alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). HEP DART will uniquely blend the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community with an increased understanding of the current and future challenges in therapeutics for liver infection, disease and cancer. OBJECTIVES: (1) Highlight advances in drug development against viral hepatitis such as HBV, HCV, and HDV. (2) Describe the latest developments in HBV curative strategies. (3) Highlight advances in drug development against NASH, fibrosis and HCC. (4) Describe novel biomarkers for viral hepatitis, liver disease, and treatment outcomes. (5) Review current treatment and vaccination guidelines for viral hepatitis; describe advancements in improved treatment regimens. (6) Understand the consequences of HBV infection and NASH in pediatrics and adolescent populations. (7) Assess the role of vaccines and therapeutic vaccines in future therapies for viral hepatitis, NASH, and co‐‐‐infections with HIV. (8) Understand the epidemiology and pathogenesis of HDV, HAV and HEV. METHODS: HEP DART 2019 comprises four days of scientific presentations, delivered in both oral and poster presentations formats via non‐‐‐concurrent sessions. Emory University, Office of Continuing Medical Education designates HEP DART for a maximum 24 category 1 credits toward the AMA Physician’s Recognition Award. HEP DART provides a relaxed and scientifically stimulating atmosphere for both PhDs and MDs to network and learn together. Support is requested to help defray costs of scholarships and travel grants for young investigators, women, visible minorities and other under‐‐‐represented delegates.